Skip to main content
SpringerLink
Log in

Prospects for development of new antimycobacterial drugs

  • REVIEW ARTICLE
  • Published:
Journal of Infection and Chemotherapy

Abstract

In this article, I have thoroughly reviewed the status of development of new antimycobacterial drugs, particularly fluoroquinolones (ciprofloxacin, ofloxacin, sparfloxacin, levofloxacin, gatifloxacin, sitafloxacin, and moxifloxacin), new macrolides (clarithromycin, azithromycin, and roxithromycin), rifamycin derivatives (rifabutin, rifapentine, and KRM-1648), and others. The main purpose of this review was to describe the in-vitro and in-vivo activities of these drugs against Mycobacterium tuberculosis and Mycobacterium avium complex. In addition, the therapeutic efficacy of these drugs in the clinical treatment of mycobacterial infections has also been briefly mentioned.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, Shimane Medical University, Izumo, Shimane 693-8501, Japan Tel. +81-853-20-2146; Fax +81-853-20-2145 e-mail: tomioka@shimane-med.ac.jp, , , , , , JP

    Haruaki Tomioka

Authors
  1. Haruaki Tomioka
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Received: December 13, 1999 / Accepted: January 5, 2000

About this article

Cite this article

Tomioka, H. Prospects for development of new antimycobacterial drugs. J Infect Chemother 6, 8–20 (2000). https://doi.org/10.1007/s101560050043

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s101560050043

Search

Navigation